Company intelligence / Profile preview
Gilgamesh Pharmaceuticals
New York, New York, United Statesgilgameshpharmaceutical.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 2
01
Overview
Two lead clinical programs (GM-1020 and GM-2505) have commenced Phase 2 studies in Major Depressive Disorder[5]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- New Chemical Entities (NCEs)NMDAR antagonists5-HT2AR agonistsneuroplastogenspsychedelics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
AbbVie (collaboration and option to license agreement worth up to $2 billion)[5][7]
Beyond the preview
Go deeper on Gilgamesh Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gilgamesh Pharmaceuticals.